
The capital injection accelerates Roamless’ push into the fast‑growing eSIM travel market, positioning it to capture demand for seamless, cost‑effective global connectivity.
The eSIM sector is entering a pivotal growth phase as airlines, hotels and fintech firms seek to offer frictionless connectivity to globetrotters. Traditional roaming contracts are being supplanted by digital SIM solutions that eliminate physical swaps and hidden fees. Roamless, founded in 2023, leverages this shift by providing a single‑click, trip‑based eSIM that works across more than 200 destinations, a breadth that rivals incumbent carriers and appeals to cost‑conscious travelers.
Roamless’ recent $12 million Series A reflects broader investor confidence in mobile‑first travel tech. Lead investor Rasmal Ventures sees the company’s scalable architecture and API‑ready platform as a gateway to deeper integration with airlines, travel agencies and financial service providers. By earmarking capital for network expansion and enhanced customer support, Roamless aims to solidify its market share and meet the rising expectations of digitally native consumers who demand instant, reliable connectivity without roaming surcharges.
Looking ahead, the company’s roadmap includes adding local phone numbers, voice, SMS and partner APIs, which could transform its eSIM offering into a full‑service communications hub. Such capabilities open new revenue streams through B2B partnerships and subscription models, while also reinforcing the value proposition for enterprise clients in the travel ecosystem. As the travel industry rebounds post‑pandemic, Roamless is well‑positioned to capitalize on the convergence of mobility, fintech and hospitality services.
Travel connectivity startup Roamless announced a $12 million Series A round led by Rasmal Ventures, with participation from Shorooq, Revo Capital, Finberg and JIMCO. The funding will be used to broaden network coverage, scale go‑to‑market efforts and deepen partnerships across travel and finance sectors.
Comments
Want to join the conversation?
Loading comments...